Overview

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Status:
Completed
Trial end date:
2017-11-15
Target enrollment:
Participant gender:
Summary
A study designed to characterize the plasma pharmacokinetic (PK) profile of CORT125134 in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134 for 14 days.
Phase:
Phase 1
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Cortisone